The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, MyelomaMarch 1, 2021
Generating recommendations for patient- reported outcome (PRO): SISAQOL-IMIMPE, Patient evidenceFebruary 18, 2021
Selinexor receives positive opinion from the EMA for the treatment of refractory myelomaAccess, MyelomaJanuary 30, 2021
Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosisJanuary 17, 2021